RDIF and Dr Reddy's tie up to manufacture coronavirus vaccine Sputnik V for India

Russia’s sovereign wealth fund, The Russian Direct Investment Fund (RDIF), has partnered with Dr. Reddy’s Laboratories to distribute and conduct clinical trials of the Sputnik V vaccine in India. According to the agreement, RDIF will be providing 100 million doses of the COVID-19 vaccine and if the trails are successful, this vaccine will be available by early-November 2020. Also, RDIF is in talks with four other Indian manufacturers who will be producing these vaccines for India.

The Sputnik V vaccine based on the adenoviral vector platform, which has been tested in >250 clinical studies, and has been found safe with no potential negative long-term consequences.

"The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations", said a statement from the fund.

Mr G V Prasad, CEO, Dr Reddy's, said, "The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.”

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.